LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

Search

Charles River Laboratories International Inc

Open

BrancheGesundheitswesen

151.07 -0.31

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

148.31

Max

152.14

Schlüsselkennzahlen

By Trading Economics

Einkommen

240M

26M

Verkäufe

-18M

984M

KGV

Branchendurchschnitt

592.3

50.291

EPS

2.34

Gewinnspanne

2.629

Angestellte

18,700

EBITDA

271M

184M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+3.29% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-638M

7.2B

Vorheriger Eröffnungskurs

151.38

Vorheriger Schlusskurs

151.07

Nachrichtenstimmung

By Acuity

25%

75%

57 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Aug. 2024, 10:30 UTC

Top News

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

3.29% Vorteil

12-Monats-Prognose

Durchschnitt 156.58 USD  3.29%

Hoch 182 USD

Tief 100 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

13 ratings

4

Buy

9

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

57 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.